Clinical development of sulforaphane-based pharmaceuticals
Evgen Pharma is a clinical stage pharmaceutical company focussed on developing novel drugs based upon sulforaphane. The Company’s lead product is Sulforadex®, a patented composition of sulforaphane and alpha-cyclodextrin.
The Company is targetting proof-of-concept clinical studies in both solid tumours (prostate cancer and breast cancer) and haematological malignancies.
Sulforadex® is a promising new pharmaceutical product in oncology as it is a non-cytotoxic agent that inhibits tumour proliferation but also targets cancer stem cells, the underlying cause of tumour recurrence and metastasis.